Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Looking hood
View:
Post by fasttrack5 on May 09, 2024 10:58pm

Looking hood

Anticipated Milestones

  • Mid 2024: Guidance on the registration path for HR+/HER2- mBC (metastatic breast cancer)
  • Q2 2024: Initiation of the GOBLET PDAC cohort investigating pelareorep/mFOLFIRINOX +/- atezolizumab and supported by PanCAN
  • H2 2024: Overall survival results from the BRACELET-1 trial
Comment by fasttrack5 on May 09, 2024 11:00pm
Subject  correction looking good
Comment by jh1970 on May 10, 2024 9:56am
Today`s market reaction says a lot . I wonder if anyone still have a hope about ONC except me.
Comment by 13X2413 on May 10, 2024 9:59am
Yep. Very disappointing. Market reaction says it all. 
Comment by Azzak34 on May 10, 2024 10:01am
Maybe if we get more alphabet meetings? 
Comment by ENEMENEMYNEMO on May 10, 2024 10:15am
Nah it's us influencers ( Buck,#'s and I) fault. Sorry guys
Comment by Azzak34 on May 10, 2024 10:33am
Haha influencers? You've been on here for 5 years and habe a 67 reputation!! Who have you influenced? 
Comment by ENEMENEMYNEMO on May 10, 2024 11:13am
My cat...he's starting to look just like me!!
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities